Alteogen Inc 196170.KQ:
ALTEOGEN ENTERS INTO A LICENSE AGREEMENT WITH BIOGEN FOR DEVELOPMENT AND COMMERCIALIZATION OF HYBROZYME™-BASED SUBCUTANEOUS BIOLOGICS
ALTEOGEN INC - TO RECEIVE $20 MILLION UPFRONT AND $10 MILLION UPON SECOND PRODUCT DEVELOPMENT
ALTEOGEN INC - ELIGIBLE FOR UP TO $549 MILLION IN MILESTONE PAYMENTS FOR TWO PRODUCTS
ALTEOGEN INC - FOLLOWING COMMERCIALIZATION, CO ENTITLED TO RECEIVE ROYALTIES BASED ON NET SALES
ALTEOGEN INC - BIOGEN HOLDS OPTION TO DEVELOP THIRD PRODUCT UNDER AGREEMENT